FISHER & PAYKEL HEALTHCARE CORPORATION LIMITED (FPH)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

FPH - FISHER & PAYKEL HEALTHCARE CORPORATION LIMITED

FNArena Sector : Medical Equipment & Devices
Year End: March
GICS Industry Group : Health Care Equipment & Services
Index: ASX100 | ASX200 | ASX300 | ALL-ORDS

Fisher & Paykel Healthcare is a designer and manufacturer of systems used in respiratory care and treatment of sleep disorders. It was separated from Fisher & Paykel and listed on the ASX and NZX in 2001. A brief Nasdaq listing was terminated in 2003. Only 1% of its revenues stems from New Zealand.

LAST PRICE CHANGE +/- CHANGE % VOLUME

$22.96

05 Dec
2022

0.120

OPEN

$22.82

0.53%

HIGH

$22.96

769,410

LOW

$22.45

TARGET
$21.50 -6.4% downside
Franking for last dividend paid out: 0%
OTHER COMPANIES IN THE SAME SECTOR
ELX . PGC . AHZ . COH . IPD . LHC . NAN . RMD . SOM . HLA . MX1 . CAT . VHT . ONE . IDX . PME . CSX . 4DX . BRN . EMV . UBI . LDX . RAP . RVA . MEB . IME . PCK . CMP . CYC . IMR . VTI . OVN . EYE . CGS . CU6 . TRJ . EBR . PEB . AT1 . CBL .
FNARENA'S MARKET CONSENSUS FORECASTS
FPH: 1
Title FY23
Forecast		 FY24
Forecast
EPS (cps) 32.6 xxx
DPS (cps) 36.8 xxx
EPS Growth N/A xxx
DPS Growth N/A xxx
PE Ratio 70.5 xxx
Dividend Yield 1.6% xxx
Div Pay Ratio(%) 113.1% xxx
This company reports in NZD.
All estimates have been converted into AUD by FNArena at present FX values.

Dividend yield today if purchased 3 years ago: 1.82%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 1.63

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages

Last ex-div: 22/06 - ex-div 20.46c (franking 0%)

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2022 FactSet UK Limited. All rights reserved
Title 201720182019202020212022
EPS Basic xxxxxxxxxxxxxxx61.6
DPS All xxxxxxxxxxxxxxx43.8
Sales/Revenue xxxxxxxxxxxxxxx1,548.1 M
Book Value Per Share xxxxxxxxxxxxxxx269.6
Net Operating Cash Flow xxxxxxxxxxxxxxx305.7 M
Net Profit Margin xxxxxxxxxxxxxxx22.95 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201720182019202020212022
Return on Capital Employed xxxxxxxxxxxxxxx24.05 %
Return on Invested Capital xxxxxxxxxxxxxxx22.78 %
Return on Assets xxxxxxxxxxxxxxx18.41 %
Return on Equity xxxxxxxxxxxxxxx24.05 %
Return on Total Capital xxxxxxxxxxxxxxx27.82 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx-36.8 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

This is work in progress. Bear with us. It'll be amazing.

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

0.5

No. Of Recommendations

4
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Credit Suisse

xx/xx/xxxx

3

xxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Morgan Stanley

xx/xx/xxxx

1

xxxxxxxxxx

-

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Macquarie

30/11/2022

3

Neutral

-

-

Fisher & Paykel Healthcare's September-half result appears to have pleased Macquarie.

No specific guidance was issued, but management pointed to sequential sales growth in consumables sales to November, and an improved gross margin.

Macquarie says that while the outlook appears solid for FY24 and FY25, the company's share price is looking expensive compared with other healthcare picks such as ResMed ((RMD)).

EPS forecasts rise 3% for FY23; 12% for FY24; and 6% for FY25.

Neutral rating retained. Target price rises to NZ$24.10, compared with the last entry in the FNArena data base in October of NZ$20.15.

FORECAST
Macquarie forecasts a full year FY23 dividend of 37.23 cents and EPS of 33.57 cents.
Macquarie forecasts a full year FY24 dividend of 38.33 cents and EPS of 42.36 cents.

Citi

xx/xx/xxxx

1

xxx

-

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial
Access Stockbroker Research History >

FPH STOCK CHART

FNArena News on FPH

1
Australian Broker Call *Extra* Edition – Dec 05, 2022

Dec 05 2022 - Daily Market Reports
2
Rudi’s View: Regrets, 2022 Delivered A Few

Dec 01 2022 - Rudi's View
3
Next Week At A Glance – 28 Nov – 2 Dec 2022

Nov 25 2022 - Weekly Reports
4
Rudi’s View: Re-Opening Opportunities In Healthcare

Nov 17 2022 - Rudi's View
5
Treasure Chest: Fisher & Paykel Healthcare

Nov 16 2022 - Treasure Chest

Latest Medical Equipment & Devices News

1
Nanosonics Recovers On Less Negative Sentiment

Nov 29 2022 - Small Caps
2
Treasure Chest: Fisher & Paykel Healthcare

Nov 16 2022 - Treasure Chest
3
Dr Boreham’s Crucible: Imricor Medical Systems

Oct 17 2022 - Small Caps
4
Market Share Gains Key to ResMed’s Outlook

Aug 15 2022 - Australia
5
Dr Boreham’s Crucible: 4D Medical

Aug 08 2022 - Small Caps
6
Treasure Chest: The Outlook For Cochlear

Jul 27 2022 - Treasure Chest
7
Nanosonics’ Q4 Surprises, But Brokers See Risk

Jul 27 2022 - Australia
8
Benefits In View For Radiology AI Adopters

Jul 11 2022 - Australia
9
Brokers Divided Over ResMed’s SaaS Acquisition

Jun 16 2022 - Australia
10
Shortages Chip Away At ResMed’s Big Break

Mar 30 2022 - Australia